3 Or 4 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.9)
  • Patent number: 10676505
    Abstract: Provided is a novel peptide having ACE inhibitory activity. Specifically, provided is a tripeptide consisting of Leu-Arg-Ala.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 9, 2020
    Assignee: SUNSTAR INC.
    Inventors: Naohisa Shobako, Kousaku Ohinata, Yuutarou Ogawa, Etsuko Kobayashi, Atsushi Ishikado, Hirohisa Suidou, Takashi Kusakari
  • Patent number: 10640533
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueous solubility, and are useful in treating various conditions or diseases associated with proteasomes.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: May 5, 2020
    Assignee: CENTRAX INTERNATIONAL, INC.
    Inventors: Jinfu Yang, Jian James Cen, Xiaoqing Michelle Fan
  • Patent number: 10526315
    Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 7, 2020
    Assignee: ORION OPHTHALMOLOGY LLC
    Inventors: Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
  • Patent number: 10513538
    Abstract: A peptide compound having a dipeptidyl peptidase-IV (DPPIV) inhibitory activity or a composition containing the peptide compound that can make a contribution to the prevention of the onset of pathology or the progression in diabetes mellitus patients or those at risk of diabetes mellitus can be provided according to the present invention by a simple method using, as a raw material, milt of a fishery product, which has been eaten for ages and has high safety. In the present invention, a peptide compound having a peptidyl peptidase-IV (DPPIV) inhibitory activity obtained in a hydrolysate of a milt protein source obtained from a fishery product is used as an active component of a composition for inhibiting DPPIV.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 24, 2019
    Assignee: MARUHA NICHIRO CORPORATION
    Inventors: Yoshinori Takahashi, Akira Kamata, Tatsuya Konishi
  • Patent number: 10441625
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 15, 2019
    Assignee: CYTOGEL PHARMA, LLC
    Inventors: Theodore E. Maione, Constantine Basil Maglaris
  • Patent number: 10363229
    Abstract: The instant invention provides methods and compositions for the treatment and prevention of cell proliferative disorders.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: July 30, 2019
    Inventor: Joan McInyre Caron
  • Patent number: 10188693
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: January 29, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
  • Patent number: 10105294
    Abstract: An object is to provide dispersion containing lipid peptide type compound useful as low molecular weight gelator, such as lipid dipeptide and lipid tripeptide, and dissolution accelerator capable of dissolving the lipid peptide type compound at lower temperature and more easily. It is also an object to provide dispersion that can form hydrogel by simpler method and under milder condition (low temperature) and from which gel can be obtained as gel having high thermal stability, and provide method for forming the gel. Dispersion including: a lipid peptide type compound in which peptide portion formed by repetition of at least two or more identical or different amino acids is bonded to lipid portion including C10-24 aliphatic group; dissolution accelerator having, in molecules thereof, hydrophilic portion and hydrophobic portion, the hydrophilic portion having betaine structure; and water; and method for producing hydrogel by use of the dispersion.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: October 23, 2018
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventor: Takayuki Imoto
  • Patent number: 10098956
    Abstract: A method for stabilizing a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 16, 2018
    Assignee: OCTAPHARMA AG
    Inventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irène Agerkvist
  • Patent number: 10040872
    Abstract: The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: August 7, 2018
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: Vincent D. Antle, Álvaro Lopes, Daniel Monteiro
  • Patent number: 10023611
    Abstract: A novel and improved process for preparation of bortezomib mannitol ester is derived, which process avoids excessive use of solvents, involves convenient, industrially feasible and economical techniques, and provides improvements in purity over processes known in the art.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: July 17, 2018
    Assignee: Cipla Limited
    Inventors: Ravikumar Puppala, Srinivas Laxminarayan Pathi, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Patent number: 9933433
    Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 3, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Essig, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Patent number: 9868763
    Abstract: The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: January 16, 2018
    Assignee: The University of Queensland
    Inventors: David Fairlie, Ligong Liu, Mei-Kwan Yau, Jacky Yung Suen, Robert Reid, Rink-Jan Lohman, Abishek Venkatasubramanian Iyer, Junxian Lim, Lindsay Charles Brown
  • Patent number: 9801845
    Abstract: Antimicrobial compositions comprising sulfur- or selenium-containing, fatty-acylated alpha-hydroxy acid compounds and methods of using said compounds or compositions to inhibit microbial growth.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 31, 2017
    Assignee: Novus International, Inc.
    Inventors: Graciela B. Arhancet, Matthew Mahoney, Scott Long, Mariya Grega, Drew L. Lichtenstein, Vivek Kuttappan, Jeffery Escobar Monestel, Mercedes Vazquez-Anon
  • Patent number: 9750822
    Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: September 5, 2017
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventor: Vincent D. Antle
  • Patent number: 9555071
    Abstract: The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD).
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: January 31, 2017
    Inventor: Thien Nguyen
  • Patent number: 9549963
    Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: January 24, 2017
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
  • Patent number: 9365614
    Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: June 14, 2016
    Assignee: Pharmascience Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • Patent number: 9199914
    Abstract: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: December 1, 2015
    Assignee: MEH ASSOCIATES, INC.
    Inventor: Mark E. Hediger
  • Patent number: 9125861
    Abstract: Methods and compositions (such as pharmaceutical compositions) for treating influenza virus type A infections in human subjects include PAR2 agonists being administered to the subject. The PAR2 agonists include small organic molecules, antibodies, and aptamers. In addition, the PAR2 agonist may be a PAR2 activating peptide. Exemplary PAR2 activating peptides include SLIGRL (SEQ ID NO: 1) and SLIGKV (SEQ ID NO: 2).
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRA)
    Inventors: Nathalie Vergnolle, Beatrice Riteau
  • Publication number: 20150141351
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 (or a pharmaceutically acceptable salt thereof), Compound 2 (or a pharmaceutically acceptable salt thereof), and ritonavir (a pharmaceutically acceptable salt thereof), which are co-formulated in amorphous solid dispersion comprising a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 21, 2015
    Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Faith Durak, Peter Hoeling, Thomas Kessler, Drazen Kostelac, Bernd Liepold, Anna Moosmann, Mirko Pauli, Karin Rosenblatt
  • Publication number: 20150140060
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventor: Gautam GHATNEKAR
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Patent number: 9034831
    Abstract: Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 19, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Feng-Jing Chen, Robert J. Schwabe
  • Patent number: 9034832
    Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: May 19, 2015
    Assignee: AbbVie Inc.
    Inventors: Yi Gao, Geoff Zhang
  • Publication number: 20150133394
    Abstract: Compositions and methods utilizing thiol-containing short peptides having the sequence Cys-Lys-Met-Cys (SEQ ID NO: 1) and optionally N- and C-terminal modifications for increasing carnitine level in muscle tissues, and treating or preventing diseases or disorders affecting muscle tissue.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventor: Josef Mograbi
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Publication number: 20150126455
    Abstract: The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 7, 2015
    Inventor: Theodore E. Maione
  • Patent number: 9023807
    Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: May 5, 2015
    Assignee: Stealth Peptides International, Inc.
    Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
  • Publication number: 20150119342
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: February 20, 2012
    Publication date: April 30, 2015
    Applicants: Universita' Degli Studi Di Milano, Fondazione Cariplo, CISI Scrl, Fondazione IRCCS Istituto Nazionale dei Tumori
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • Publication number: 20150119317
    Abstract: The present invention is directed to an oral solid dosage formulation of Asunaprevir, 1,1-dimethylethyl[(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods of using the formulation in the treatment and/or inhibition of the hepatitis C virus and infections caused thereby.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Rhye Hamey, Preetanshu Pandey, Dilbir S. Bindra, Chandra Vemavarapu, Robert Kevin Perrone
  • Publication number: 20150118315
    Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.
    Type: Application
    Filed: June 13, 2012
    Publication date: April 30, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20150119330
    Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Patrick A. McGee, Kenneth W. Jackson, Victoria J. Christiansen
  • Patent number: 9018170
    Abstract: A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: April 28, 2015
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ayelet Altman, Doris Saltkill, Tomer El-Gad, Dalton L. Tomlinson
  • Publication number: 20150111838
    Abstract: This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. As well as cyclodextrin complexation methods of formulating a peptide proteasome inhibitor (e.g., a compound of formula (1)-(5) or a pharmaceutically acceptable salt thereof) with one or more cyclodextrins. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. For example, homogenous solutions of a compound of formula (5) (carfilzomib) can be obtained at a pharmaceutically useful pH (e.g., about 3.5) and at higher concentrations (e.g., about 5 mg/mL) than could be obtained without one or more cyclodextrins and the processes of complexation between the compound and one or more cyclodextrins provided herein.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 23, 2015
    Inventors: Evan Lewis, Peter Schwonek, Sean Dalziel, Mouhannad Jumaa
  • Publication number: 20150111837
    Abstract: The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: A-Thr-Lys-Pro-B-C-D-X, where: A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gin, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg, Thr-Lys-Pro-Arg-Gly.
    Type: Application
    Filed: May 28, 2013
    Publication date: April 23, 2015
    Applicant: "IVIX" Ltd.
    Inventors: Nikolay Fedorovich Myasoedov, Lyudmila Alexandrovna Andreeva, Dmitriy Viktorovich Golikov
  • Publication number: 20150099709
    Abstract: The present invention relates to a use of a compound having ghrelin receptor agonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for treatment of diseases including achlorhydria in which abnormal gastric acid secretion is involved. In addition, the present invention relates to the method of treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agents. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound of the present invention or a pharmaceutically acceptable salt thereof for the treatment of said diseases.
    Type: Application
    Filed: May 27, 2013
    Publication date: April 9, 2015
    Inventors: Nobuyuki Takahashi, Masaki Sudo, Kaoru Shimada, Hiroaki Wakabayashi
  • Publication number: 20150093463
    Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 2, 2015
    Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
  • Publication number: 20150093370
    Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN
  • Patent number: 8993523
    Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Christopher Sean Straub
  • Publication number: 20150087578
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Application
    Filed: August 25, 2014
    Publication date: March 26, 2015
    Inventor: Thomas LUGER
  • Publication number: 20150087605
    Abstract: Disclosed are compositions and methods for treating anthrax, inhibiting anthrax toxins and inhibiting anthrax toxin-induced cytotoxicity. Carboxylic acid-containing small molecules can be used in the methods and compositions disclosed herein, for example, sulindac and derivatives thereof may be used. Methods of screening for carboxylic acid-containing small molecules that can be used to treat anthrax are disclosed. Targeting the anthrax toxin reduces the risks of anthrax spores.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 26, 2015
    Inventors: J. Manuel Perez Figueroa, Oscar Santiesteban, Charalambos Kaittanis
  • Patent number: 8987214
    Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Yi Gao, Geoff Zhang
  • Patent number: 8980837
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: March 17, 2015
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
  • Publication number: 20150072942
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: April 8, 2014
    Publication date: March 12, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Patent number: 8975232
    Abstract: The present invention provides macrocyclic compounds of Formula (I): pharmaceutically acceptable salts thereof; and pharmaceutical compositions thereof, wherein R1, R2, R3, R4, RE, RF, RG, RH, RI, f, g, h, n, and m are as defined herein. The present invention further provides methods of synthesizing these macrocyclic compounds, and methods of their use and treatment. Certain aspects of the present invention relate to modulation of kinase activity, and in the treatment of kinase-associated diseases or disorders.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 10, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Ralph E. Kleiner
  • Publication number: 20150065437
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Application
    Filed: March 20, 2014
    Publication date: March 5, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventors: Liping Liu, Lawrence Gu
  • Publication number: 20150056215
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.
    Type: Application
    Filed: April 4, 2013
    Publication date: February 26, 2015
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Patent number: 8962798
    Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: February 24, 2015
    Assignee: Helix BioMedix, Inc.
    Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
  • Patent number: 8962565
    Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2, cosmetic or pharmaceutical compositions comprising at least one peptide compound of general formula (I) in a physiologically acceptable medium, and methods for cosmetic treatment of skin are disclosed. The peptide compounds of general formula (I) were demonstrated to be agents making it possible to influence the pigmentation of the skin and skin appendages, by ensuring optimal transfer of the melanosomes to the keratinocytes, so as to make the skin tone uniform owing to an effect on the SCF/c-Kit signaling pathway. The compounds, compositions, and methods treat or attenuate age-related pigmentation defects and the effects of photoaging on the skin.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: February 24, 2015
    Assignee: ISP Investments Inc.
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto